Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TransMedics (TMDX) Non-Current Assets (2018 - 2026)

TransMedics has reported Non-Current Assets over the past 8 years, most recently at $430.6 million for Q4 2025.

  • For Q4 2025, Non-Current Assets rose 40.32% year-over-year to $430.6 million; the TTM value through Dec 2025 reached $1.4 billion, up 31.6%, while the annual FY2025 figure was $430.6 million, 40.32% up from the prior year.
  • Non-Current Assets for Q4 2025 was $430.6 million at TransMedics, up from $333.0 million in the prior quarter.
  • Over five years, Non-Current Assets peaked at $430.6 million in Q4 2025 and troughed at $4.7 million in Q1 2021.
  • A 5-year average of $148.4 million and a median of $75.5 million in 2023 define the central range for Non-Current Assets.
  • Biggest five-year swings in Non-Current Assets: dropped 9.29% in 2021 and later skyrocketed 1148.75% in 2024.
  • Year by year, Non-Current Assets stood at $9.8 million in 2021, then soared by 95.34% to $19.2 million in 2022, then skyrocketed by 916.45% to $195.4 million in 2023, then soared by 57.05% to $306.9 million in 2024, then surged by 40.32% to $430.6 million in 2025.
  • Business Quant data shows Non-Current Assets for TMDX at $430.6 million in Q4 2025, $333.0 million in Q3 2025, and $332.4 million in Q2 2025.